153P A phase II study of cabozantinib in metastatic/unresectable refractory GIST from a tertiary care centre in India

ESMO rare cancers. 2026 Open access

Read full text
Authors: N. Ventrapragada, S. Rastogi, C. Rajegowda, S. Shamim, R. Yadav, N R Dash, K.A. Singh, A. Singh
DOI: 10.1016/j.esmorc.2026.100359
Cited by: 0

Abstract

Ripretinib, the current standard fourth-line therapy in advanced gastrointestinal stromal tumours (GIST), is largely unavailable in LMICs. Cabozantinib is a multikinase inhibitor with activity against MET, VEGFR2, and KIT. This study evaluated the efficacy and safety of cabozantinib in patients with metastatic/advanced GIST who had progressed after ≥3 prior tyrosine kinase inhibitors (TKIs).

Fields of Study & Subjects

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100359–100359
Publication date
1 March 2026
Language
EN